Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Julie Wang et al.|New England Journal of Medicine|2019Cited by 1.7k
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaJacalyn Rosenblatt, David Avigan|Blood|2010Cited by 226
Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoireGiulia Cheloni, David Avigan, Dimitra Karagkouni et al.|Nature Communications|2025Cited by 18
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myelomaWilliam C. Pilcher, Shaji Kumar, Lijun Yao et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 14
Abstract 2257: Activation and clonotypic expansion of the native T cell repertoire identifies durable response to CD19 CAR T cell therapyDimitra Karagkouni, Ioannis S. Vlachos, Giulia Cheloni et al.|Cancer Research|2023Cited by 1